EMEA-000817-PIP02-11-M01

Key facts

Invented name
Influsplit Tetra and associated names
Active substance
  • Purified antigen fractions of inactivated split virion influenza virus type A, H1N1
  • influenza virus type A, H3N2
  • influenza virus type B, Victoria lineage
  • influenza virus type B, Yamagata lineage
Therapeutic area
Vaccines
Decision number
P/0171/2013
PIP number
EMEA-000817-PIP02-11-M01
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of influenza infection
Route(s) of administration
Intramuscular use
Contact for public enquiries
GSK Vaccines S.r.l.

Tel. +1 438 899 8201
Email: eu.paediatric-plans@gsk.com
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-000817-PIP02-11-M01
Compliance opinion date
21/04/2017
Compliance outcome
positive

Decision

How useful was this page?

Add your rating